Gene Expression in Pancreatic Cancer (NEOPANC-01)
A Phase 0, Pre-operative, Window-of-opportunity Study to Assess Gene Expression in Patients With Resectable, Locally Advanced, or Metastatic Pancreatic Cancer (NEOPANC-01)
Sponsor: University of Oxford
Terminated
Study was closed early due to low numbers of evaluable patients
Listed as NCT03531125, this observational or N/A phase trial focuses on Pancreatic Cancer and remains terminated or withdrawn. Sponsored by University of Oxford, it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 4 earlier versions
-
Apr 2020 — Nov 2020 [monthly]
Terminated
Status: Recruiting → Terminated
-
Nov 2019 — Apr 2020 [monthly]
Recruiting
-
May 2019 — Nov 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — May 2019 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .